Cancer Research Technology
Log in Register
Menu

Anti-Cisplatin modified DNA [CP9/19]

Invented by Dr Michael Tilby at University of Newcastle upon Tyne

Info

Catalogue Number 151464
Applications ELISA FACS IHC IP DB
Antigen/Gene or Protein Targets Cisplatin modified native DNA
Reactivity N/A
Relevance This antibody enables the quantification of cisplatin-induced adducts on DNA. This antibody has also been recently used for isolation of DNA fragments carrying adducts to enhance the sensitivity of subsequent PCR-based analyses and is central to ongoing studies of variation in the nature of cisplatin adducts formed in different cell lines.
Antibody CP9/19 recognises only the intra-strand cross-links formed by cisplatin between adjacent purines.
Host Rat
Immunogen Cisplatin modified native DNA
Subclass IgG2a
Positive Control RNA/DNA
Myeloma Used Y3.AG.1.2.3
Recommended Growing Conditions DMEM + 10%FCS + Glu + Pen/Strep
Notes Alternative Name: ICR4
Research Area DNA Damage and Repair, Epigenetics & Nuclear Signalling

References: 27 entries

Powell et al. 2015. Sci Rep. 5:7975. PMID: 25609656.

IP

3D-DIP-Chip: a microarray-based method to measure genomic DNA damage.

Europe PMC ID: 25609656

Kothandapani et al. 2012. Exp Cell Res. 318(16):1973-86. PMID: 22721696.

Downregulation of SWI/SNF chromatin remodeling factor subunits modulates cisplatin cytotoxicity.

Europe PMC ID: 22721696

Kothandapani et al. 2011. J Biol Chem. 286(16):14564-74. PMID: 21357694.

Novel role of base excision repair in mediating cisplatin cytotoxicity.

Europe PMC ID: 21357694

Meczes et al. 2005. Biochem Pharmacol. 70(12):1717-25. PMID: 16259963.

Specific adducts recognised by a monoclonal antibody against cisplatin-modified DNA.

Europe PMC ID: 16259963

Deverman et al. 2002. Cell. 111(1):51-62. PMID: 12372300.

Bcl-xL deamidation is a critical switch in the regulation of the response to DNA damage.

Europe PMC ID: 12372300

Veal et al. 2001. Clin Cancer Res. 7(8):2205-12. PMID: 11489793.

Veal et al. 2001. Clin Cancer Res. 7(8):2205-12. PMID: 11489793.

Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy.

Europe PMC ID: 11489793

Strobeck et al. 2000. Proc Natl Acad Sci U S A. 97(14):7748-53. PMID: 10884406.

BRG-1 is required for RB-mediated cell cycle arrest.

Europe PMC ID: 10884406

Ghazal-Aswad et al. 1999. Ann Oncol. 10(3):329-34. PMID: 10355578.

Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels.

Europe PMC ID: 10355578

Welters et al. 1999. Ann Oncol. 10(1):97-103. PMID: 10076728.

The potential of plantinum-DNA adduct determination in ex vivo treated tumor fragments for the prediction of sensitivity to cisplatin chemotherapy.

Europe PMC ID: 10076728

Peng et al. 1997. Br J Cancer. 76(11):1466-73. PMID: 9400943.

Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.

Europe PMC ID: 9400943

Cross et al. 1996. Int J Cancer. 66(3):404-8. PMID: 8621265.

Effect of quercetin on the genotoxic potential of cisplatin.

Europe PMC ID: 8621265

Evans et al. 1994. Cancer Res. 54(6):1596-603. PMID: 8137265.

Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation.

Europe PMC ID: 8137265

Tilby et al. 1991. Cancer Res. 51(1):123-9. PMID: 1703029.

Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody.

Europe PMC ID: 1703029


Add a reference

References: 27 entries

Powell et al. 2015. Sci Rep. 5:7975. PMID: 25609656.

IP

3D-DIP-Chip: a microarray-based method to measure genomic DNA damage.

Europe PMC ID: 25609656

Kothandapani et al. 2012. Exp Cell Res. 318(16):1973-86. PMID: 22721696.

Downregulation of SWI/SNF chromatin remodeling factor subunits modulates cisplatin cytotoxicity.

Europe PMC ID: 22721696

Kothandapani et al. 2011. J Biol Chem. 286(16):14564-74. PMID: 21357694.

Novel role of base excision repair in mediating cisplatin cytotoxicity.

Europe PMC ID: 21357694

Meczes et al. 2005. Biochem Pharmacol. 70(12):1717-25. PMID: 16259963.

Specific adducts recognised by a monoclonal antibody against cisplatin-modified DNA.

Europe PMC ID: 16259963

Deverman et al. 2002. Cell. 111(1):51-62. PMID: 12372300.

Bcl-xL deamidation is a critical switch in the regulation of the response to DNA damage.

Europe PMC ID: 12372300

Veal et al. 2001. Clin Cancer Res. 7(8):2205-12. PMID: 11489793.

Veal et al. 2001. Clin Cancer Res. 7(8):2205-12. PMID: 11489793.

Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy.

Europe PMC ID: 11489793

Strobeck et al. 2000. Proc Natl Acad Sci U S A. 97(14):7748-53. PMID: 10884406.

BRG-1 is required for RB-mediated cell cycle arrest.

Europe PMC ID: 10884406

Ghazal-Aswad et al. 1999. Ann Oncol. 10(3):329-34. PMID: 10355578.

Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels.

Europe PMC ID: 10355578

Welters et al. 1999. Ann Oncol. 10(1):97-103. PMID: 10076728.

The potential of plantinum-DNA adduct determination in ex vivo treated tumor fragments for the prediction of sensitivity to cisplatin chemotherapy.

Europe PMC ID: 10076728

Peng et al. 1997. Br J Cancer. 76(11):1466-73. PMID: 9400943.

Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.

Europe PMC ID: 9400943

Cross et al. 1996. Int J Cancer. 66(3):404-8. PMID: 8621265.

Effect of quercetin on the genotoxic potential of cisplatin.

Europe PMC ID: 8621265

Evans et al. 1994. Cancer Res. 54(6):1596-603. PMID: 8137265.

Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation.

Europe PMC ID: 8137265

Tilby et al. 1991. Cancer Res. 51(1):123-9. PMID: 1703029.

Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody.

Europe PMC ID: 1703029


Add a reference

References: 27 entries

Powell et al. 2015. Sci Rep. 5:7975. PMID: 25609656.

IP

3D-DIP-Chip: a microarray-based method to measure genomic DNA damage.

Kothandapani et al. 2012. Exp Cell Res. 318(16):1973-86. PMID: 22721696.

Downregulation of SWI/SNF chromatin remodeling factor subunits modulates cisplatin cytotoxicity.

Kothandapani et al. 2011. J Biol Chem. 286(16):14564-74. PMID: 21357694.

Novel role of base excision repair in mediating cisplatin cytotoxicity.

Meczes et al. 2005. Biochem Pharmacol. 70(12):1717-25. PMID: 16259963.

Specific adducts recognised by a monoclonal antibody against cisplatin-modified DNA.

Deverman et al. 2002. Cell. 111(1):51-62. PMID: 12372300.

Bcl-xL deamidation is a critical switch in the regulation of the response to DNA damage.

Veal et al. 2001. Clin Cancer Res. 7(8):2205-12. PMID: 11489793.

Veal et al. 2001. Clin Cancer Res. 7(8):2205-12. PMID: 11489793.

Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy.

Strobeck et al. 2000. Proc Natl Acad Sci U S A. 97(14):7748-53. PMID: 10884406.

BRG-1 is required for RB-mediated cell cycle arrest.

Ghazal-Aswad et al. 1999. Ann Oncol. 10(3):329-34. PMID: 10355578.

Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels.

Welters et al. 1999. Ann Oncol. 10(1):97-103. PMID: 10076728.

The potential of plantinum-DNA adduct determination in ex vivo treated tumor fragments for the prediction of sensitivity to cisplatin chemotherapy.

Peng et al. 1997. Br J Cancer. 76(11):1466-73. PMID: 9400943.

Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy.

Cross et al. 1996. Int J Cancer. 66(3):404-8. PMID: 8621265.

Effect of quercetin on the genotoxic potential of cisplatin.

Evans et al. 1994. Cancer Res. 54(6):1596-603. PMID: 8137265.

Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation.

Tilby et al. 1991. Cancer Res. 51(1):123-9. PMID: 1703029.

Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody.


Add a reference


This reagent does not have any reviews at the moment.